Orexo Announces Results Confirming The Clinical Profile Of OX17 In Reflux Disease (GERD)
Apr 2nd 2008Drug InformationAcid Reflux/GERD
New clinical data from a phase II study confirms the competitive profile of Orexo’s product OX17 in GERD patients, i.e. fast, effective and sustained inhibition of gastric acid production, a prerequisite for effective symptom relief in the patient. The result demonstrates the clinical potential of OX17 and is an important step in the development of a competitive product. GERD, gastroesofageal reflux disease, is a common ailment in the Western world.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
